GlaxoSmithKline: ViiV Healthcare Posts Positive Results for HIV Study
August 15 2018 - 2:49AM
Dow Jones News
By Maryam Cockar
GlaxoSmithKline PLC (GSK.LN) said Wednesday that its subsidiary
has reported positive results in its first phase 3 study for an
injectable two-drug regimen for the treatment of HIV.
GSK said ViiV Healthcare Ltd.'s study showed similar efficacy of
a once-a-month, injectable two-drug regimen of cabotegravir and
rilpivirine drugs compared with a standard daily, oral three-drug
regimen.
If the two-drug regimen is approved it would give people living
with HIV one month between each dose of antiretroviral therapy,
changing HIV treatment from 365 doses days a year to 12 doses, John
Pottage, chief scientific and medical officer of ViiV Healthcare,
said.
ViiV Healthcare, a specialist HIV company, is majority owned by
GSK with Pfizer Inc. (PFE) and Shionogi & Co. Ltd.
(4507.TO).
Write to Maryam Cockar at maryam.cockar@dowjones.com
(END) Dow Jones Newswires
August 15, 2018 02:34 ET (06:34 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Jun 2024 to Jul 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Jul 2023 to Jul 2024
